FDA rejects Lipocine's testosterone drug for third time

The U.S. Food and Drug Administration on Monday declined to approve Lipocine Inc's oral drug to treat a condition that results in lower production of male sex hormone for the third time, sending the drug developer's shares down 34%.

from Reuters: Health News https://ift.tt/2NyYTY5
via IFTTT